微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | 27.14% | 7.94% | 11.05% | 120/157 | 50.55% | 泽璟制药 | 94.64% | 行业排名> |
| 2025-12-31 | 24.44% | -8.59% | -6.47% | 128/157 | 50.61% | 海创药业 | 99.82% | 行业排名> |
| 2025-06-30 | 26.13% | -7.11% | 3.92% | 125/157 | 14.83% | 海创药业 | 98.62% | 行业排名> |
| 2025-03-31 | 25.15% | -20.15% | -5.96% | 123/157 | 31.96% | 海创药业 | 99.57% | 行业排名> |
| 2024-12-31 | 26.74% | 90.62% | -2.18% | 126/157 | 51.88% | 海创药业 | 99.52% | 行业排名> |
| 2024-09-30 | 27.33% | 41.16% | -2.83% | 121/157 | 22.51% | 艾力斯 | 96.74% | 行业排名> |
| 2024-06-30 | 28.13% | 38.93% | -10.67% | 121/157 | 33.12% | 首药控股 | 98.96% | 行业排名> |
| 2024-03-31 | 31.49% | 57.2% | 124.49% | 113/157 | 51.76% | 迪哲医药 | 97.73% | 行业排名> |
| 2023-12-31 | 14.03% | -47.34% | -27.56% | 141/157 | 51.61% | 百利天恒 | 97.99% | 行业排名> |
| 2023-09-30 | 19.36% | -34.11% | -4.36% | 137/157 | 32.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-06-30 | 20.25% | -33.8% | 1.08% | 135/157 | 38.42% | 迈威生物 | 98.93% | 行业排名> |
| 2023-03-31 | 20.03% | -33.18% | -24.8% | 132/157 | 52.97% | 迈威生物 | 99.59% | 行业排名> |
| 2022-12-31 | 26.64% | -28.48% | -9.37% | 128/157 | 53.83% | 迈威生物 | 99.8% | 行业排名> |
| 2022-09-30 | 29.39% | -21.98% | -3.91% | 112/157 | 5.64% | 迈威生物 | 99.46% | 行业排名> |
| 2022-06-30 | 30.58% | -21.25% | 2.02% | 114/157 | 20.99% | 迈威生物 | 99.75% | 行业排名> |
| 2022-03-31 | 29.98% | -27.08% | -19.51% | 110/157 | 54.39% | 迈威生物 | 99.67% | 行业排名> |
| 2021-12-31 | 37.24% | -18.01% | -1.13% | 114/157 | 55.2% | 迈威生物 | 99.44% | 行业排名> |
| 2021-09-30 | 37.67% | -18.65% | -3.01% | 99/157 | 46.77% | 迈威生物 | 98.57% | 行业排名> |
| 2021-06-30 | 38.84% | -17.18% | -5.52% | 104/157 | 47.23% | 首药控股 | 99.93% | 行业排名> |
| 2021-03-31 | 41.11% | -14.77% | -9.5% | 81/157 | 54.13% | 艾力斯 | 99.41% | 行业排名> |
| 2020-12-31 | 45.42% | -9.62% | -1.91% | 94/157 | -148.64% | 艾力斯 | 98.7% | 行业排名> |
| 2020-09-30 | 46.31% | -8.73% | -1.25% | 79/157 | 56.43% | 艾力斯 | 99.4% | 行业排名> |
| 2020-06-30 | 46.89% | -6.05% | -2.78% | 81/157 | 54.17% | 首药控股 | 99.94% | 行业排名> |
| 2020-03-31 | 48.23% | -0.81% | -4.03% | 66/157 | 55.17% | 泽璟制药 | 99.96% | 行业排名> |
| 2019-12-31 | 50.26% | 13.23% | -0.94% | 76/157 | -1242.15% | 微芯生物 | 95.14% | 行业排名> |
| 2019-09-30 | 50.73% | 17.08% | 1.64% | 61/157 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-06-30 | 49.91% | 19.53% | 2.64% | 64/157 | 55.21% | 微芯生物 | 95.81% | 行业排名> |
| 2019-03-31 | 48.63% | 16.19% | 9.56% | 59/157 | 51.07% | 微芯生物 | 96.09% | 行业排名> |
| 2018-12-31 | 44.39% | 3.36% | 2.43% | 83/157 | -211.97% | 微芯生物 | 96.11% | 行业排名> |
| 2018-09-30 | 43.33% | -1.18% | 3.77% | 65/157 | 54.14% | 微芯生物 | 95.5% | 行业排名> |
| 2018-06-30 | 41.76% | -7.36% | -0.22% | 69/157 | 53.53% | 微芯生物 | 96.27% | 行业排名> |
| 2018-03-31 | 41.85% | -6.37% | -2.54% | 66/157 | 54.16% | 贝达药业 | 95.47% | 行业排名> |
| 2017-12-31 | 42.94% | -1.91% | -2.07% | 74/157 | 52.55% | 贝达药业 | 95.51% | 行业排名> |
| 2017-09-30 | 43.85% | -2.16% | -2.72% | 53/157 | 49.09% | 贝达药业 | 95.54% | 行业排名> |
| 2017-06-30 | 45.07% | 1.26% | 0.84% | 53/157 | 47.91% | 贝达药业 | 95.74% | 行业排名> |
| 2017-03-31 | 44.7% | 3.04% | 2.1% | 45/157 | 46.94% | 退市金泰 | 96.19% | 行业排名> |
| 2016-12-31 | 43.78% | -5.3% | -2.32% | 58/157 | 48.46% | 贝达药业 | 95.81% | 行业排名> |
| 2016-09-30 | 44.82% | -6.7% | 0.68% | 37/157 | 46.19% | 退市金泰 | 95.93% | 行业排名> |
| 2016-06-30 | 44.52% | -10.52% | 2.61% | 43/157 | 46.26% | 贝达药业 | 95.58% | 行业排名> |
| 2016-03-31 | 43.38% | -10.31% | -6.16% | 38/157 | 43.86% | 贝达药业 | 95.89% | 行业排名> |